Compare Amphastar Pharmaceuticals Inc (AMPH) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs MasterCard Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while MasterCard Inc trades at $563.47 (market cap $493.34B). The key difference: MasterCard Inc is far larger — about 571× Amphastar Pharmaceuticals Inc's market cap, and MasterCard Inc pays a 0.62% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | MA | |
|---|---|---|
Market Cap | $863.95M | $493.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $598.96 |
52-Week Low | $16.87 | $471.55 |
Enterprise Value | $1.26B | $506.38B |
Volume | — | 4,635,698 |
Dividend Yield | — | 0.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Mastercard (MA) trades at $561.44, down 0.27% on the day, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 EPS of $5.04, beating estimates, and maintains robust profitability with a net income margin of 46.34%. Recent news highlights institutional buying and AI-driven payment innovations, while analyst consensus remains strongly positive.
Outlook is favorable with a consensus price target of $660.85, implying ~18% upside. Risks include payment industry disruption from stablecoins and competitive pressures. Earnings growth and high institutional ownership support continued strength, but investors should monitor evolving payment technologies and macroeconomic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
